Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $376000.0.

  • Adma Biologics' Interest & Investment Income fell 4354.35% to $376000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 611.08%. This contributed to the annual value of $2.1 million for FY2024, which is 2968.46% up from last year.
  • Adma Biologics' Interest & Investment Income amounted to $376000.0 in Q3 2025, which was down 4354.35% from $400000.0 recorded in Q2 2025.
  • Adma Biologics' Interest & Investment Income's 5-year high stood at $666000.0 during Q3 2024, with a 5-year trough of $2269.0 in Q2 2022.
  • In the last 5 years, Adma Biologics' Interest & Investment Income had a median value of $376000.0 in 2025 and averaged $272421.1.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first plummeted by 9110.77% in 2021, then soared by 2511631.64% in 2023.
  • Adma Biologics' Interest & Investment Income (Quarter) stood at $2759.0 in 2021, then fell by 12.03% to $2427.0 in 2022, then skyrocketed by 25116.32% to $612000.0 in 2023, then dropped by 2.29% to $598000.0 in 2024, then tumbled by 37.12% to $376000.0 in 2025.
  • Its Interest & Investment Income stands at $376000.0 for Q3 2025, versus $400000.0 for Q2 2025 and $608000.0 for Q1 2025.